Ad Header



The Pulse of the Pharmaceutical Industry

FDA approves Gilead’s hep C drug Epclusa

Written by: | | Dated: Tuesday, June 28th, 2016

The U.S. Food and Drug Administration approved Gilead Sciences Inc’s drug for treating chronic hepatitis C virus infection.

The drug, Epclusa, is approved for use in combination with ribavirin.

Epclusa is the first drug to treat all six major types of hepatitis C virus infection.

Gilead shares were up 4 pct at $81.03 in morning trading on the Nasdaq.



(Reporting by Shailesh Kuber in Bengaluru; Editing by Don Sebastian)

Source: Reuters Health


Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation